EyeSense, a developer of ophthalmic self-diagnostic systems for glucose monitoring of diabetes patients, has entered into a strategic partnership with Qiagen, to expand the range of applications for the growing segment of point-of-need testing and individualized treatment of patients.
The partners intend to develop a new optical measurement technology for blood glucose monitoring in diabetes patients, based on Qiagen’s ESE fluorescence-based optical technology and on Eyesense’s glucose sensing technology.
Qiagen acquired a minority equity stake in EyeSense, and attained royalty rights for future commercialization.
EyeSense’s blood glucose monitoring (BGM) approach marks an important step in diabetes field and the company’s painless device is based on a non-invasive ophthalmic diagnostic system.
EyeSense intends to launch the new device in 2013 and the financial details of the partnership have not been disclosed.
EyeSense CEO and co-founder Achim Muller said the collaboration with Qiagen is an important validation of EyeSense’s progress to date, and substantially strengthens their development efforts.
"With its leadership in optical measurement systems, Qiagen is an ideal partner to help us maximize our development and engineering know-how, take our technology to the next level, and put our advanced monitoring devices in the hands of patients at an accelerated pace," Muller said.